Broadening its presence in the CNS space, Roche’s Genentech has licensed the worldwide rights to develop and commercialise UCB’s tau-targeting antibody UCB0107 for the treatment of Alzheimer’s disease. The deal is potentially worth US$2.1 B, of which US$120 M will be paid upfront. UCB0107 will complement Roche’s other tau inhibitor semorinemab (RG6100), which was in-licensed from AC Immune in June 2012 and is currently in a Phase II study in patients with prodromal to mild AD.